The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Swiss pharma giant Roche today announced positive top-line results from year two of the EMBARK trial, a global, randomized, ...
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained ...
Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
GlobalData on MSN10d
Roche reports positive topline outcomes from DMD treatment trialRoche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...
The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.
Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys (delandistrogene moxeparvovec) as a gene therapy for treating Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback